Relationship between lipid profile and monocyte to highdensity lipoprotein ratio with disease severity in chronic obstructive pulmonary disease patients

Year 2022, Volume: 4 Issue: 3, 260 - 264, 26.07.2022

Sertan Bulut , Harun Karamanlı , Zeynep Erayman Özen , Metin Tahhan , Çiğdem Biber

https://doi.org/10.38053/acmj.1094819

Abstract

Aim: To examine lipid profile and monocyte to high density lipoprotein ratio ratio (MHR) values in stable chronic obstructive pulmonary disease patients.
Material and Method: Patients admitted to our hospital with the diagnosis of chronic obstructive pulmonary disease (COPD) between 01.01.2014 - 01.01.2020 were included in the study and evaluated retrospectively. According to the COPD guideline, two main groups were formed as A+B and C+D. Demographic characteristics, hemogram, C-Reaktif protein (CRP), albumin, lipid profile values were analyzed.
Result: In our study, there were 360 cases, 293 (81.4%) of which were male. The mean age was 67.61±8.7 years. There were 162 cases (45%) in the A+B group and 198 (55%) in the C+D group.White blood cell (WBC) , neutrophil, lymphocyte, neutrophil/lymphocyte ratio (NLR), monocytes, hemoglobin, CRP, Albumin, high density lipoprotein (HDL), monocyte to HDL ratio (MHR) were found to be different at the level of statistical significance, while cholesterol, triglyceride and low density lipoprotein (LDL) were not at this level of significance. When evaluated with multivariate regression analysis afterwards, it was observed that the statistical significance levels of MHR, CRP and albumin values continued.
Conclusion: We think that high MHR rate, high CRP, and low albumin values in stable COPD patients may be a stimulant for increased disease severity.

Keywords

Albumin, CRP, COPD, HDL, lipit profile, MHR

References

• GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease; 2021
• Saymaz Z T, Çelik D, Yıldız M, Ertan Ö. The effects of D-dimer high rates on prognosis and mortality in chronic obstructive respiratory disease. Anatolian Curr Med J 2022; 4: 44-50.
• Agust, A, Lisa D. Edwards,Stephen I, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators: Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PloS one 2012; 7.
• Wang Z. L. Evolving role of systemic inflammation in comorbidities of chronic obstructive pulmonary disease. Chinese Med J 2010; 123: 3467-78.
• Breyer M K, Martijn A. Spruit,Corrine K, et al. Prevalence of metabolic syndrome in COPD patients and its consequences. PloS one 2014; 9.
• Assmann G, Gotto Jr A M. HDL cholesterol and protective factors in atherosclerosis. Circulation 2004; 109: 8.
• Welty FK. How do elevated triglycerides and low HDL-cholesterol affect inflammation and atherothrombosis?. Curr Cardiol Rep 2013; 15: 1-13.
• Ancuta P, Wang J, Gabuzda D. CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J Leukoc Biol 2006; 80:1156-64.
• Biswas SK. Does the Interdependence between Oxidative Stress and Inflammation Explain the Antioxidant Paradox? Oxid Med Cell Longev 2016.
• Canpolat U, Çetin EH, Cetin S et al. Association of monocyte to HDL cholesterol ratio with slow coronary flow is linked to systemic inflammation. Clin Appl Thromb Hemost 2016; 22: 476 82.
• Yakar H I, Kanbay A. Could monocyte level/HDL cholesterol ratio predict cardiovascular diseases in patients with COPD. Niger J Clin PractNiger J Clin Pract 2020; 234: 450-5.
• Markelić I,Iva H,,Dunja R, et al. Lipid profile and atherogenic indices in patients with stable chronic obstructive pulmonary disease. Nutr Metab Cardiovasc Dis 2021; 31: 153-161.
• Nillawar A N, Joshi K B, Patil S B, Jayshree S, Suhas J. B. Evaluation of HS-CRP and Lipid Profile in COPD. J Clin Diag Res JCDR 2013; 7: 801.
• Can U, Yerlikaya F H, Yosunkaya, S. Role of oxidative stress and serum lipid levels in stable chronic obstructive pulmonary disease. Journal of the Chinese Med Assoc 2015; 78: 702-8.
• Gunay S, Sariaydin M, Acay A. New predictor of atherosclerosis in subjects with COPD: atherogenic indices. Respir Care 2016; 61: 1481-87.
• Beti Z-I, Jagoda S, Dejan D, et al. The level of cholesterol in COPD patients with severe and very severe stage of the disease. Open access Macedonian J Med Sci 2016; 4: 277.
• Özkan S. Risk assessment and rate of readmission within 30 days of discharge after hospitalization for acute exacerbation of chronic obstructive pulmonary disease. Tuberk Toraks 2021; 69: 328-37.
• Melih B, Gulru P, Hulya Ş, et al. Does the benefit from pulmonary rehabilitation differ between phenotypes in chronic obstructive pulmonary disease? Eurasian J Pulmonol 2021; 23: 32.
• Yakar HI, Kanbay A. A new predictor to determine the exacerbation and treatment of chronic obstructive pulmonary disease: eosinophil/neutrophil ratio. Tuberkuloz Toraks 2020; 68: 260-7.
• Xilin Y, Wing YS, Ronald C, et al. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2011; 34: 375-80.
• Garrison RJ, Kannel WB, Feinleib M, et al. Cigarette smoking and HDL cholesterol the Framingham offspring study. Atherosclerosis 1978; 30: 17-25.
• İn E, Kuluözturk M, Öner Ö, Deveci F. The importance of neutrophil-to-lymphocyte ratio in chronic obstructive pulmonary disease. Turkish Thoracic J 2016; 17: 41.
• El-Gazzar AG, Kamel M H, Elbahnasy OKM, El-Naggar MES. Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients. Exp Rev Respir Med 2020; 14: 111-6.